Rapid Development of Migraine Therapies Offers New Hope
Physicians offer perspectives on newly approved products to prevent migraine.
When Disease Hijacks the Brain
Learn about the most insightful article Dr Lazzara has ever read in a research journal.
John Corboy, MD: The DISCO-MS Trial
The professor of neurology at Colorado University spoke about the ongoing phase IV trial to determine the safety of DMT discontinuation in MS.
Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy
Neurology News Network for the week of Oct. 12, 2018.
Cell Therapies Offer Hope But Are Often Misused
Cellular therapies have the potential to make a meaningful difference for patients with neurological disorders, if used correctly.
IncobotulinumtoxinA Reduces Sialorrhea Across Neurological Disorders
IncobotulinumtoxinA significantly reduced unstimulated salivary flow rate for patients with sialorrhea.
Evobrutinib Significantly Reduces T1 Gd+ Lesions in Relapsing Multiple Sclerosis
This marks the first time a BTK inhibitor showed a clinical proof-of-concept in relapsing MS.
Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis
The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.
Thomas Leist, MD: Immune Reconstitution Therapy for Multiple Sclerosis
The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.
Patisiran Shows Sustained Improvements in Disease Progression for hATTR Amyloidosis
Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.
Probing Headaches: A Diagnostic Challenge Quiz
What differentiates migraine from underlying intracranial pathology that may require neuroimaging, like tumors, abscesses, aneurysms, or hemorrhages? Test your skills with this 5-question quiz.
Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response
The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.
Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMS
The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.
Cladribine Tablets Safety Profile Reaffirmed With Long-Term Data
An updated safety analysis of the therapy in patients with relapsing MS, up to 10 years, has shown no new safety signals.
Subcutaneous Immunoglobulin Effective Alternative to Intravenous for Myasthenia Gravis
Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.
Eculizumab's Myasthenia Gravis Benefits Sustained in Long-Term Extension Study
Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.
Richard Rudick, MD: Using Data to Personalize MS Care
The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.
New AUC for Lumbar Puncture, CSF Testing in Diagnosis of Alzheimer Disease
The guidance provides clinicians with tools allowing for earlier and more accurate diagnosis of Alzheimer disease.
John Corboy, MD: Taking Patients Off Of Disease-Modifying Therapy
The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.
Earlier Treatment With Ocrelizumab Shows Favorable Results in Relapsing, Primary Progressive MS
Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.
New Classification for an Old Problem: Chronic Pain in America
Over 10 million Americans suffer from debilitating chronic pain, according to new data that provides insights into the unrelenting problem of pain in America.
Siponimod NDA Accepted by FDA for Secondary Progressive MS
If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.
Eva Winnebeck, PhD: Temporal Dynamics of Sleep
The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.
Telehealth, Remaining Innovative as Technology Changes
The medical director of digital health at Cleveland Clinic spoke about the role telehealth plays in a society where technology constantly advances and changes.
Neural Insights: The Jealousy Switch
Brain injury and stroke studies have revealed that jealousy is indeed "in your head”-specifically in the left part of the cerebral cortex.
Novel Post-Stroke Intervention Suggests Tailored Approach Can Reduce Recurrence Risk
DESERVE is one of the first interventions potentially demonstrating the capacity to decrease racial and ethnic disparities in stroke risk reduction.
Developing Cannabinoid Derivative EHP-101 for Multiple Sclerosis
With a phase I trial of the therapy underway, EHP-101 is one step closer to potentially showing an effect on the pathology of multiple sclerosis.
Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSA
The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.
Eric Pina-Garza, MD, on Perampanel For Pediatrics with Partial-Onset Seizures
The pediatric neurologist discussed the importance of the recent FDA approval of perampanel in pediatrics with partial-onset seizures with or without secondarily generalized seizures.
Duchenne Muscular Dystrophy Gene Therapy Shows Positive Results
In a small trial, the AAVrh74.MHCK7.micro-dystrophin therapy has shown high levels of transduced micro-dystrophin expression.
